By Bruce Gil
Popular weight-loss drugs like Wegovy and Zepbound are boosting the use of healthcare in the U.S., leading to an uptick in patients getting diagnosed and starting prescriptions for other conditions, according to a new analysis by health data firm Truveta.
The firm analyzed thousands of electronic patient records between 2020 and 2024 and found a noticeable bump in first-time diagnoses of sleep apnea, cardiovascular disease, and type 2 diabetes just days after a patient started a prescription for a GLP-1 weight-loss drug.
These drugs are bringing people who previously avoided medical care into the doctor’s office. In partnership with Truveta, Reuters interviewed a number of patients and physicians who said that some overweight patients seeking GLP-1s treatments have been hesitant to visit a doctor or go in for routine tests for years due to “stigma and bias they often encounter.”
Because of this, once they do finally go to a doctor seeking a GLP-1 prescription these patients also end up getting diagnosed with other obesity-related conditions.
Truveta researchers found that for every 1,000 patients with a first-time GLP-1 prescription in 2024, 42 ended up getting diagnosed with type 2 diabetes within 15 days, compared with 32 in 2020. During the same period, the number of sleep apnea diagnoses per 1,000 patients rose to 11 from 8, while the number of cardiovascular disease diagnoses jumped to 15 from 13.
The company’s CEO, Michael Farrell, told investors in a recent meeting that GLP-1 drugs are “bringing people into primary care like never before.”
GLP-1 medications are a class of drugs, made popular by Novo Nordisk’s (NVO+0.13%) diabetes drug Ozempic, that mimic a hormone that regulates appetite and blood sugar and have become highly sought after as treatments for obesity and Type 2 diabetes.
Popular brands on the market also include Ozempic’s sister drug Wegovy and Eli Lilly’s (LLY-0.02%) Zepbound. Soaring demand for these meds has turned Novo Nordisk and Eli Lilly into the largest pharma companies in the world.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
